Emergency deployment of genetically engineered veterinary vaccines in Europe

Bahar Ramezanpour, Jean de Foucauld, Jeroen Kortekaas*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)

Abstract

On the 9th of November 2015, preceding the World Veterinary Vaccine Congress, a workshop was held to discuss how veterinary vaccines can be deployed more rapidly to appropriately respond to future epizootics in Europe. Considering their potential and unprecedented suitability for surge production, the workshop focussed on vaccines based on genetically engineered viruses and replicon particles. The workshop was attended by academics and representatives from leading pharmaceutical companies, regulatory experts, the European Medicines Agency and the European Commission. We here outline the present regulatory pathways for genetically engineered vaccines in Europe and describe the incentive for the organization of the pre-congress workshop. The participants agreed that existing European regulations on the deliberate release of genetically engineered vaccines into the environment should be updated to facilitate quick deployment of these vaccines in emergency situations.

Original languageEnglish
Pages (from-to)3435-3440
JournalVaccine
Volume34
Issue number30
DOIs
Publication statusPublished - 2016

Keywords

  • Directive
  • Europe
  • Genetically engineered
  • Live-attenuated
  • Replicon
  • Reverse genetics
  • Vaccine
  • Virus

Fingerprint Dive into the research topics of 'Emergency deployment of genetically engineered veterinary vaccines in Europe'. Together they form a unique fingerprint.

Cite this